Is CKD prevalence of 10-13% in Europe, US and China a realistic number or is there overdiagnosis of CKD? Marc E De Broe.
|
|
- Clarence Bradley
- 5 years ago
- Views:
Transcription
1 Is CKD prevalence of 10-13% in Europe, US and China a realistic number or is there overdiagnosis of CKD? Marc E De Broe November 2016
2 An example of partnership Maremar Maladies rénales au Maroc
3
4 CKD IN MOROCCO: Early detection and intervention project Kidney damage : proteinuria, hematuria, sediment imaging Confirmation of proteinuria, hematuria ; chronicity of egfr GFR (ml/min/1.73m 2 ) CKD Kidney damage with normal or increased GFR Kidney damage with mildly decreased GFR +90 CKD CKD2 Moderately decreased GFR CKD3 Severely decreased GFR CKD4 Kidney failure <15 (or dialysis) CKD5 The National Kidney Foundation Kidney Quality Outcomes Initiative (KDOQI) KDIGO (2012)Chronic Kidney Disease (CKD) Classification System
5 CKD IN MOROCCO: Early detection and intervention project Prevalence of CKD stages 1 through 4 in Norway and the USA No confirmed albuminuria; no chronicity of egfr decrease Hallan SI et al: JASN 17: , 2006
6 Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000 Calculated false +proteinuria (based on a small sample 50%), no chronicity of decreased egfr Coresh J et al: JASN 16: , 2005
7 CKD IN MOROCCO: Early detection and intervention project All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on adults in Taiwan No confirmed albuminuria; no egfr chronicity Wen CP et al: Lancet 371: , 2008
8 CKD IN MOROCCO: Early detection and intervention project Prevalence of chronic kidney disease in China: a cross-sectional survey No confirmed albuminuria; no egfr chronicity Albuminuria was defined as a urinary albumin:creatinine ratio > 30 mg/g creatinine. CKD was defined as egfr <60 ml/min per 1.73 m 2 or albuminuria. All prevalences are adjusted for synthesised weights. egfr= estimated glomerular filtration rate. CKD: chronic kidney disease. Zhang L et al: Lancet 379: , 2012
9 CKD IN MOROCCO: Early detection and intervention project Prevalence of CKD in different studies around the world according to the KDOQI staging guidelines. CKD 1 and 2 GFR <90, GFR ml/min 1.73m2 AND albuminuria CKD GFR < 60, 30, 15 ml/min 1.73m Number US adults 8.8% 9.4% 19,000,000 JASN 2005 Norway JASN % 510,000 Taiwan 11.9% 200,000 Wen, Lancet 2008 ( ) Mainland China 10.2% 140,000,000 Zeng, Lancet 2012 ( ) Maremar 2.9 % 150,000 manus (2015)
10 MAREMAR: Four main objectives To estimate the prevalence of CKD, hypertension obesitas,diabetes in a representative randomized sample of the adult population of Morocco (26 70 years of age) To identify subjects at risk to develop CKD, To identify health related habits associated with an increased risk to develop CKD, To establish an intervention program for a follow-up period of 5 years.
11 Measurements: estimated Glomerular Filtration Rate (egfr) using the MDRD equation (Modification of Diet in Renal Disease) serum creatinine (Scr) using a methodology traceable to the Scr reference system (NIST) (GC-IDMS). Quality control /monthly,in case of hemolysis a new sample was analysed. Chronicity (3m.) microproteinuria (mpr) using the Hemocue method and nephelometry (quaility control), dipstick =+ +/macroproteinuria (MPR) using dipstick (=++ or more) on two morning midstream urine samples over 2-3 weeks fasting glycemia NIST= National Institute of Standards and Technology IDMS= isotope dilution mass spectrometry transport system from H.C. to lab within hours
12 SAMPLE SIZE CALCULATION,STRATIFIED RANDOM SAMPLE Based on this sample size, (10.000, 9%of adult population of the 2 towns) we expect to recruit: between 200 and 800 CKD patients (2-8% of screened population) with signs of renal impairment, needing further clinical investigations and appropriate treatment (28) between 2000 and 3000 patients (20-30% of screened population) with pathological findings (hypertension, diabetes and/or microalbuminuria) at risk to develop CKD, to whom a preventive treatment for 5 years (based on a prevalence of 20% hypertension and 6% diabetes in Morocco with or without microalbuminuria (29) ) will be offered. between 1000 and 2000 subjects (10-20% of screened population) with two or more health related habits increasing the risk for the development of renal impairment, that will be invited for a new screening after 1, 3 and 5 years (29, 33-37)) With a total sample size of participants, the 95% confidence interval for the observed prevalence of CKD will be lower than 1%. This means that, even with a CKD prevalence of e.g. 7,5%, we will be able to state with 95% confidence that the real prevalence will be not lower than 7% and not higher than 8%.
13 Sampling KHEMISSET EL JADIDA Population years Sampling Voters list Recruitment Stratified random sample (9% of eligible people) Period of six months
14 Sampling Stratified randomized sample, voters list 1000 participants / centre in total 10 health centers, (HC) = 10,000 subjects 5 health centers of screening/city in two cities (40 subjects/week x25 weeks = 1000 /health center ) Age Sex M y N N y N N y N N F
15 VOTERS LIST First list(1999) obtained after one year (2008) of negotiations was useless. Missing,wrong adressess Second updated list was given after the elections of 2009 Second list turned out to be usefull
16 Organization, training & monitoring 19 official meetings 10 education meetings, workshops and training sessions 38 local visits 88 people involved at different levels
17 Screening 1 st visit (Investigations) Dipstick Albuminuria 3X sitting Glycemia Creatininemia Understanding is essential
18 Screening 2 nd visit (1 week) Confirmation of pathological findings Dipstick > + Microalbuminuria > 20mg/l SAP>140 mmhg and/or DAP> 90 mmhg
19 How to perform a midstream urine sample illitaration rate: 30% Dirk De Weerdt
20 CKD IN MOROCCO: Early detection and intervention project Recruitment: response rates at first visit Response rates during the different phases of the Maremar recruitment procedure Total number : n= 10524
21 Prevalence of hypertension (SAP 140 mmhg and/or DAP 90 mmhg) years 7.2% years 20.3% years 39.2% All 16.7% Correction: based on the demographic structure of the population Hypertension confirmed in 1003/1458 cases %
22 Prevalence of obesity (BMI 30 kg/m²) years 18.3% years 28.1% years 25.9% All 23.2% %
23 Prevalence of obesity markers BMI >30 W-H ratio > 1 M, 0,85 F Waist > 104 M, 80 F 1, 2 or 3 11,3 36,4 24,2 4,6 53,5 29,7 6,3 58,1 32, ,6 45, Male Female All Health outcomes : no difference between men and woman
24 Prevalence of hyperglycemia 1.26g/l Mean glycemia was 1.13 g/l (SD 0.49) years 6.3% years 18.2% years 27.4% All 13.8% Corrected prevalence of glycemia between g/l was 30.3% %
25 CKD IN MOROCCO: Early detection and intervention project egfr (MDRD) in the adult population of Morocco: Percentiles within the gender and age categories
26 CKD IN MOROCCO: Early detection and intervention project egfr(mdrd) in the adult population of Morocco: Gaussian distribution of three age categories 0.3% 0% 0.3% 13.7% 85.8% 0.2% 0.1% 0.9% 28.5% 70.2% 0.4% 0.4% 5.8% 42.1% 51.2%
27 CKD IN MOROCCO: Early detection and intervention project
28 CKD IN MOROCCO: Early detection and intervention project KDOQI-classification based on egfr and proteinuria (confirmed dipstick investigation) prot.:negative CKD1-5 = 4.2% study population CKD1: 0.7% CKD2: 0.7% CKD3: 2.2% CKD4-5: 0.5%
29 CKD IN MOROCCO: Early detection and intervention project KDIGO-classification based on egfr, proteinuria and hematuria (confirmed dipstick investigation) CKD1-5 = 7.4% study population
30 CKD IN MOROCCO: Early detection and intervention project egfr age (MDRD formula) KDIGO Kidney International May 2016 M Ben Gharby et al
31 CKD IN MOROCCO: Early detection and intervention project egfr age: MDRD formula MAREMAR Moroccan adult male population Dutch adult male population males P95 P75 P50 P25 P05 Kidney Int 2007
32 CKD IN MOROCCO: Early detection and intervention project egfr age: MDRD formula Japanese adult male population MAREMAR Moroccan adult male population Arab-Berber population: egfr = 175 x s(c) x [Age] x [0.742 if female] x [1.212 if black] Japanese population: Baba M 2015 Plus One egfr = 194 scr Age (if female 0.739)
33
34 Life expectancy according to chronic kidney disease stages egfr proteinuria Gansevoort RT et al: Lancet 2013; 382:
35 Mortality risk in elderly swedish women with CKD (KDIGO definition) Observed Hazard Ratio (HR-and 95% CI) in women age years (egfr >60 ml/min/1.73m 2 as reference) according to egfr estimating formulas fully adjusted for co-morbidity CKD 3A CKD 3B-5 CKD-EPI= 1.4 ( ) MDRD= 1.3 ( ) Lund-Malmo= 1.1 ( ) BIS1= 1.1 ( ) Cockcroft-Gault= 1.3 ( ) none= p<0.05 CKD-EPI= 3.5 ( ) MDRD= 3.4 ( ) Lund-Malmo= 3.2 ( ) BIS1=3.1 ( ) Cockcroft-Gault=2.2 ( ) all p=<0.007 Malmgrem L, et al. Nephron 2015; 136:
36 CKD IN MOROCCO: Early detection and intervention project Prevalence of CKD in different studies around the world according to the KDOQI staging guidelines. CKD 1 and 2 GFR <90, GFR ml/min 1.73m2 AND albuminuria CKD GFR < 60, 30, 15 ml/min 1.73m Number US adults 8.8% 9.4% 19,000,000 JASN 2005 Norway JASN % 510,000 Taiwan 11.9% 200,000 Wen, Lancet 2008 ( ) Mainland China 10.2% 140,000,000 Zeng, Lancet 2012 ( ) Maremar ,000 manus (2015)
37 CKD IN MOROCCO: Early detection and intervention project Demography and CRF population pyramids Morocco Belgium Prevalence of CRF egfr< 60 ml/min/1.73m y 6.6% 41-55y 1.3% 26-40y 0.5% 1.6% 4.7% Reasons for Overdiagnosis
38 CKD IN MOROCCO: Early detection and intervention project Low prevalence of CKD in Maremar The 2 nd reason is overdiagnosing : single investigation of proteinuria. Most published reports, dealing with epidemiology of CKD, confirmation of the proteinuria was not performed ( good quality??). False positivity of urine analysis dipstick % Malaysia KI 2013 : 57% dipstick ++/ % The chronicity criterion was never used mainly because follow-up data on serum Many factors can influence protein/albumin excretion such as obesity, age, gender, distant inflammation, high blood pressure, remote infection and drug use (Rosuvastatine) creatinine were not collected 3th reason is the lack of confirmation of chronicity of decreased egfr (CKD 3A : 32.2% false positives, CKD3B : 7.4% false positives) (NDT 30; supl.4 ;2015) Equation problem?
39 CKD IN MOROCCO: Early detection and intervention project 3th reason is the lack of confirmation of chronicity of decreased egfr (CKD 3A : 32.2% false positives, CKD3B : 7.4% false positives) The chronicity criterion was never used mainly because follow-up data on serum creatinine were not collected Bruck c et al NDT 2015 The prevalence of CKD might have been SLIGHTLY overestilated using single creatinine and albuminuria measurements Bruck C et al JASN 27; 2015 )
40 CKD Prevalence Varies across the European General Population The prevalence of CKD might have been slightly overestimated using single creatinineand albuminuria measurements. However, this will not have influenced the variation of CKD prevalence across studies, as all estimations will be equally affected. page 2143 right side K Brück et al JASN 2016, 27, pg 2135 The chronicity criterion was never used mainly because follow-up data on serum creatinine were not collected K Brück et al, NDT 30; 2015
41 CKD IN MOROCCO: Early detection and intervention project Chronicity of egfr measurement False positives: CKD 3A: 32.2% CKD 3B: 7.4% Clear improvement of accuracy
42 False positive rates for single determinations of egfr in diagnosis of CKD A population-based study of the inhabitants of Tromso, Norway (n=58,000) 38,241 screened: had an MDRD egfr of ml/min/1.73m 2 (17.9%) - median age= 75 years egfr repeated after 3 months: - 88 had egfr <30 ml/min/1.73m had egfr >60 ml/min/1.73 m2 False positive rate for diagnosis of CKD (Stages 3-5) = 31.7% Eriksen B and Ingebretsen O, Kidney Int 2006; 69:
43 Inker La et al CJASN 2016 Lifetime Risk of Stage 3 5 CKD in a Community-Based Sample in Iceland Estimates are lower than reported using single estimtates of egfr Condition 4 only one measurment of egfr Condition 1,2,3 at least two determinations of egfr
44 A false positive result was found in 67.2% of the subjects with mild proteinuria (+) decreasing substantially to 28.7% in subjects with overt (++/++++) proteinuria. mild or overt proteinuria at first visit: n= % of study population confirmed mild or overt proteinuria: n= % of study population Chronicity of egfr: The vast majority (75%) of false positives found in the subjects with CKD3A ; 32.2% had an egfr exceeding 60ml/min/1.72m 2. 90% of studies do not evaluatetd chronicity
45 CKD IN MOROCCO: Early detection and intervention project Assessment of CKD CKD assessment based on egfr 1 egfr,+ unconfirmed proteinuria/hematuria (most studies) with proteinuria with proteinuria and/or hematuria 7.0% 14.0% 2 egfr + confirmed proteinuria (some studies) 4.2% 7.4% 3 Chronicity egfr + conf. proteinuria/hematuria (KDIGO 2013) MAREMAR 3.9% 6.7% 3+ correction for total populations 2.9% 5.1% Mild or overt proteinuria at first visit (n=513): 4.9% of study population A false positive result was found in 67.2% of the subjects with mild proteinuria (+) and decreased substantially to 28.7% in subjects with overt (++/++++) proteinuria. mild or overt proteinuria at first visit: confirmed mild or overt proteinuria: n= % of study population n= % of study population Chronicity of egfr: The vast majority (75%) of false positives found in the subjects with CKD3A ; 32.2% had an egfr exceeding 60ml/min/1.72m 2.
46 Under/Over estimation of CKD Demography Confirm proteinuria 3-4 weeks Chronicity egfr < 60 5 months < 60 MDRD EPI formula and others, clearly under or above 3 th % line
47 51.2% CKD3A have egfr > P03, no proteinuria, no hematuria, no chronic kidney disease (CKD) 77 71
48 CKD IN MOROCCO: Early detection and intervention project CONCLUSION Lack of confirmation of proteinuria and no demonstration of chronicity of a decreased egfr are the main reasons for the inflation ( up to 60%or more) of the CKD prevalence in published reports. The choice of arbitrary single thresholds of egfr for classifying CKD 3 to 5 inevitably leads to substantial over-diagnosis (false positives) of CKD3 in the subjects 50 years of age or more, particularly in those without proteinuria, hematuria, or hypertension. It also leads to under-diagnosis (false negatives) of CKD in younger individuals without proteinuria,with an egfr above 60 ml/min/1.73 m2 and below the third percentile of their age/sex category who can t be classified by the current KDIGO guidelines.. Kidn. Intern. Mohammed Ben Gharbi et al May 2016
49 CKD IN MOROCCO: Early detection and intervention project Subjects aged 50 years of age or more with an egfr between 60-45ml/min/1.73m2 without proteinuria, hematuria and hypertension can t be considered as CKD3A. The use of a third percentile egfr level as cutoff, based on age-/sex-specific reference values of egfr, allows the detection of these false positives and negatives. The physiological aging process of the kidney, along with a decrease in renal function, is rather comparable across populations of different races. There is urgent need for quality prevalence studies of CKD confirming the relative low prevalence observed in Maremar, stopping the inflation of CKD based on very weak data Kidn. Intern. Mohammed Ben Gharbi et al May 2016
50 Who is who Steering Committee - A. Belghiti Alaoui - R. Bayahia - M. Benghanem Gharbi - A. Bitane - M. De Broe - E. El Haroudi - O. Elmenzhi - B. Ramdani - S.S. Youssef Docters, nurses, administrative personnel of the health centers Scientific Committee - M. De Broe - M. Benghanem Gharbi - M. Arrayhani - R. Bayahia - A. Belghiti Alaoui - N. Benahadi - S.S. El Khayat - O. Elmenzhi - M. Elseviers - B. Ramdani - E. Trabelssi - M. Zamd
51 Mohammed Ben Gharbi, Monique Elseviers, Mohammed Zamd
52 CKD IN MOROCCO: Early detection and intervention project Pieter Bruegel (Antwerpen ) The Blind leading the Blind
53 Inker La et al CJASN 2016 Lifetime Risk of Stage 3 5 CKD in a Community-Based Sample in Iceland Estimates are lower than reported using single estimtates of egfr Condition 4 only one measurment of egfr Condition 1,2,3 at least two determinations of egfr
Full Review. Why overestimate or underestimate chronic kidney disease when correct estimation is possible?
Nephrol Dial Transplant (2017) 32: ii136 ii141 doi: 10.1093/ndt/gfw267 Full Review Why overestimate or underestimate chronic kidney disease when correct estimation is possible? Marc E. De Broe 1, Mohamed
More informationTHE NKF-KDOQI (2002) CKD DEFINITION AND CLASSIFICATION SYSTEM: Limitations and Problems
THE NKF-KDOQI (2002) CKD DEFINITION AND CLASSIFICATION SYSTEM: Limitations and Problems Richard J. Glassock, MD, MACP David Geffen School of Medicine at UCLA KDIGO Controversies Conference London, UK October
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationEvaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationEpidemiology of chronic kidney disease: think (at least) twice!
Clinical Kidney Journal, 2017, vol. 10, no. 3, 370 374 doi: 10.1093/ckj/sfw154 Advance Access Publication Date: 27 February 2017 Editorial Comment EDITORIAL COMMENT Epidemiology of chronic kidney disease:
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSummary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationCharacteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests
Renal Tests Holly Kramer MD MPH Associate Professor of Public Health Sciences and Medicine Division of Nephrology and Hypertension Loyola University of Chicago Stritch School of Medicine Renal Tests 1.
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationImpact of a single egfr and egfr-estimating equation on chronic kidney disease reclassification
Research Jennifer A Hirst, Maria DLA Vazquez Montes, Clare J Taylor, José M Ordóñez-Mena, Emma Ogburn, Vanshika Sharma, Brian Shine, Tim James and FD Richard Hobbs Impact of a single egfr and egfr-estimating
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPrimary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationKEEP 2.0 Annual Data Report Chapter Five
KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More information2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives
Evaluation of egfr and mgfr in CKD Use of CKD staging with case scenario Assessment of kidney function in CKD in adults Learning Objectives 台大雲林分院楊淑珍藥師 2017/03/11 Chronic Kidney Disease (CKD) Based on
More informationKEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56
21 Summary Figures S32 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar
More informationIntroduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population
3176 Nephrol Dial Transplant (2011) 26: 3176 3181 doi: 10.1093/ndt/gfr003 Advance Access publication 16 February 2011 Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population In light of the 2017 blood pressure guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), this year we examine hypertension control
More informationFrom Department of Medicine, David Geffen School of Medicine at UCLA.
FROM ISHIB 2009 THE PROS AND CONS OF STAGING CHRONIC KIDNEY DISEASE Background and Objectives: In 2002 the National Kidney Foundation Kidney Disease Outcomes Quality Initiative presented a new definition
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationKEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64
211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationChronic Renal Failure Followed by Acute Renal Failure
Chronic Renal Failure Followed by Acute Renal Failure Dr Emre Karakoç Çukurova Üniversity Department of Medical ICU Terminology Acute Kidney Injury Chronic Kidney Disease Acute Kidney Disease Acute kidney
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Age and Kidney Weight renal weight and thickening of the vascular intima Platt et al. Gerentology 1999;45:243-253
More informationOnline clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary
Online clinical pathway for chronic kidney disease (CKD) in primary care February 27, 2015 Dr. Kerry McBrien University of Calgary FACULTY/PRESENTER DISCLOSURE Faculty: Kerry McBrien Relationships with
More informationCKD EVIDENCE TABLES - ALL CHAPTERS
CKD EVIDENCE TABLES - ALL CHAPTERS CHAPTER 3-CKD GUIDELINE CONTENTS: 3.1. INVESTIGATION OF CKD 3.2. FACTORS AFFECTING THE BIOLOGICAL AND ANALYTICAL VARIABILITY OF GFR ESTIMATED FROM MEASUREMENT OF SERUM
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationDonation from Old Living Donors How safe is it? Safe for recipient or donor?
Donation from Old Living Donors How safe is it? Safe for recipient or donor? Pr Lionel Rostaing Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation CHU Grenoble Alpes France lrostaing@chu-grenoble.fr
More informationConcept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
More informationNice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care
Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care Paula D Souza Senior CKD Nurse Specialist Royal Devon and Exeter Healthcare Trust Introduction Background What
More informationRenal function vs chemotherapy dosing
Renal function vs chemotherapy dosing Jenny Casanova Senior Clinical Pharmacist Repatriation General Hospital Daw Park 1 Methods of estimating renal function Cockcroft-Gault (1976) C-G using ideal vs actual
More informationDepartment of Clinical Pathology, Faculty of Medicine Padjadjaran University-Dr. Hasan Sadikin General Hospital 2
Original Article Comparison of Estimated Glomerular Filtration Rate Mean Value of HARUS 15-30-60, HADI, and ASIAN Fomula Accuracy in Diabetes Mellitus Type 2 Sylvia Rachmayati, 1 Ida Parwati, 1 Abdul Hadi
More informationLife Science Journal 2014;11(10)
Performance of CKD-EPI versus MDRD among Diabetic Egyptians Khaled Abou-Seif, Yahya Makkeyah, Maha Behairy and Mohamed Mostafa Ali Internal Medicine & Nephrology Department, Ain Shams University Mahabehairy80@gmail.com
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationKEEP 2009 Summary Figures
S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationCKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral
CKD IN THE CLINIC Family Physician Refresher Course Lisa M. Antes, MD April 19, 2017 No disclosures Session Content 1. 2. Recommendations for commonly used medications in CKD Basic principles /patient
More informationThe National Quality Standards for Chronic Kidney Disease
The National Quality Standards for Chronic Kidney Disease Dr Robert Lewis Chief of Service, Wessex Kidney Centre, Portsmouth Specialist Committee Member Quality Standard for Chronic Kidney Disease, NICE
More informationCorrespondence should be addressed to Maisarah Jalalonmuhali;
Hindawi International Journal of Nephrology Volume 2017, Article ID 2901581, 7 pages https://doi.org/10.1155/2017/2901581 Research Article Comparative Performance of Creatinine-Based Estimated Glomerular
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationLaboratory Assessment of Diabetic Kidney Disease
Laboratory Assessment of Diabetic Kidney Disease Andrew S. Narva 1 and Rudolf W. Bilous 2 In Brief Regardless of etiology, chronic kidney disease (CKD) is identified by two laboratory tests: 1) estimated
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationMeasurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE
Measurement and Estimation of renal function Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE 1 2 How to estimate GFR? How to measure GFR? How to estimate GFR? How to measure GFR?
More informationAssessing Renal Function: What you Didn t Know You Didn t Know
Assessing Renal Function: What you Didn t Know You Didn t Know Presented By Tom Wadsworth PharmD, BCPS Associate Clinical Professor UAA/ISU Doctor of Pharmacy Program Idaho State University College of
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationIdentifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationRENAL FUNCTION ASSESSMENT ASSESSMENT OF GLOMERULAR FUNCTION ASSESSMENT OF TUBULAR FUNCTION
Measured GFR (mgfr mgfr) and Estimated t GFR (egfr egfr) R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RENAL FUNCTION ASSESSMENT ASSESSMENT OF GLOMERULAR FUNCTION ASSESSMENT OF TUBULAR
More informationCarboplatin Time to Drop the Curtain on the Dosing Debate
Carboplatin Time to Drop the Curtain on the Dosing Debate Jon Herrington, Pharm.D., BCPS, BCOP Judith Smith, Pharm.D., BCOP, CPHQ, FCCP, FISOPP Scott Soefje, Pharm.D., MBA, BCOP Heimberg J, et al. N Engl
More informationDr Poorva Jain MBChB MRCP. Page 1 of 375
Can Routinely Collected Primary Care Data Determine the Prevalence of Chronic Kidney Disease And Predict Clinical Events In Patients With Stages 3 of the Disease? Dr Poorva Jain MBChB MRCP Page 1 of 375
More informationGlomerular Filtration Rate Estimations and Measurements. Pierre Delanaye, MD, PhD University of Liège CHU Sart Tilman BELGIUM
Glomerular Filtration Rate Estimations and Measurements Pierre Delanaye, MD, PhD University of Liège CHU Sart Tilman BELGIUM Summary Estimating GFR (creatinine, egfr, cystatin C) Measuring GFR Summary
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationΕκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης
Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης Ιατρική Σχολή ΑΠΘ Νοσοκομείο ΑΧΕΠA Θεσσαλομίκη Kidney in body homeostasis Excretory function Uremic toxins removal Vascular volume maintainance Fluid-electrolyte
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationGFR and Drug Dosage Adaptation: Are We still in the Mist?
GFR and Drug Dosage Adaptation: Are We still in the Mist? Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM I have no conflict of interest to declare
More informationAn update on the obesity epidemics in CKD and in ESRD. Does it really matter?
EURECA-m 2011 An update on cutting-edge Cardiovascular and Renal Medicine themes. An update on the obesity epidemics in CKD and in ESRD. Does it really matter? Francesca Mallamaci BMI>30 25 Ireland 20
More information8/12/2016. Diabetes Management Across the Spectrum of Kidney Function. Andrew Bzowyckyj. Learning Objectives. Ashley Crowl
Diabetes Management Across the Spectrum of Kidney Function Andrew Bzowyckyj PharmD, BCPS, CDE Clinical Assistant Professor School of Pharmacy University of Missouri-Kansas City Kansas City, MO Ashley Crowl
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationThe Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD
The Link Between Acute and Chronic Kidney Disease John Arthur, MD, PhD Conventional Dogma Conventional dogma was that if a patient survived and recovered from AKI, he was unlikely to have long-term sequela.
More informationEgfr non african american vs african american
Buscar... Egfr non african american vs african american 15-2-2017 Chronic TEENney disease (CKD) is a condition characterized by a gradual loss of TEENney function over time. To read more about TEENney
More informationBurden of chronic kidney disease on the African continent: a systematic review and meta-analysis
Kaze et al. BMC Nephrology (2018) 19:125 https://doi.org/10.1186/s12882-018-0930-5 RESEARCH ARTICLE Open Access Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis
More informationMeasurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE
Measurement and Estimation of renal function Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE 1 2 How to estimate GFR? How to measure GFR? How to estimate GFR? How to measure GFR?
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationMasatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health
176 J Occup Health, Vol. 54, 2012 J Occup Health 2012; 54: 176 180 Journal of Occupational Health Evaluation of Validity of the Urine Dipstick Test for Identification of Reduced Glomerular Filtration Rate
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More information